Pharmaceuticals News and Research

RSS

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of its novel antibiotic, Restanza™ that support its use in a hospital setting.

8 Jul 2010

Alimera Sciences submits MAA for Iluvien to MHRA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals has submitted a Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom for Iluvien (fluocinolone acetonide intravitreal insert).

8 Jul 2010

Shire files patent infringement lawsuit against Zydus

Shire plc, the global specialty biopharmaceutical company, announces that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the U.S. District Court for the District of Delaware against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals, Inc. for the infringement of U.S. Patent No. 6,773,720.

8 Jul 2010

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada. With the approval of the IND, US hospitals will also participate in this study.

8 Jul 2010

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.

8 Jul 2010

Jubilant Organosys Board approves amalgamation of SML & PMSL and demerger of APP business

Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, today announced that the Board has approved the scheme of amalgamation and demerger. This is to enable focused growth and value realization across operating entities.

8 Jul 2010

Biopharmaceutical Nanotechnology Scientific Forum to take place in Philadelphia between August 16-18

IQPC presents Biopharmaceutical Nanotechnology Scientific Forum taking place August 16-18 in Philadelphia, PA.

From IQPC Ltd 8 Jul 2010

Article related to MN-166 mechanism of action included in PNAS USA

MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported that the June 22, 2010 issue of Proceedings of the National Academy of Sciences USA included an article related to the mechanism of action of MN-166 (ibudilast), as an emerging therapeutic for neurological disorders.

8 Jul 2010

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

Selvita sp. z o.o., from Krakow, Poland and Orion Corporation from Espoo, Finland (ORNBV) today announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita's proprietary program for the treatment of Alzheimer's disease and other cognitive disorders. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.

8 Jul 2010

UTHealth Biotechnology Commercialization Center leases over three-quarters of available space

The University of Texas Health Science Center at Houston (UTHealth) announced that its Biotechnology Commercialization Center (BCC) has leased more than three-quarters of its available space to eight Texas-based startups in less than a year. The center's focus is to assist biotech entrepreneurs and small companies with the translation of discoveries into innovative health solutions.

8 Jul 2010

Optics Express publishes special focus issue on lung cancer imaging research

Advanced imaging technologies that promise to improve the development of effective drugs to treat lung cancer are the focus of the current special issue of Optics Express, an open-access journal published by the Optical Society (OSA). Research featured in the special focus issue on Imaging in Diagnosis and Treatment of Lung Cancer outlines standardized approaches to measure and compare tumor size, as well as to validate the accuracy of such measurements under defined settings.

8 Jul 2010

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

Nymox Pharmaceutical Corporation reported today positive new results from pooled analysis of completed clinical trials of NX-1207, the Company's investigational drug for BPH. The trial data shows that patients receiving NX-1207 recorded significant quantitative improvement in the important symptom of urgent need to urinate.

8 Jul 2010

New York Times examines India's growing influence on global drug industry

"India's drug industry — on track to grow about 13 percent this year, to just over $24 billion — was once notorious for making cheap knockoffs of Western medicines and selling them in developing countries. But India, seasoned in the basics of medicine making, is now starting to take on a more mainstream role in the global drug industry, as a result of recent strengthening of patent law here and cost pressures on name-brand drug makers in the West," the New York Times writes.

8 Jul 2010

SurModics licenses biodegradable polymer implant technology to Clinuvel

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne, Australia. Under the agreement, the Company's SurModics Pharmaceuticals unit has licensed certain of its biodegradable polymer implant technology to Clinuvel for the treatment of sun-induced skin disorders. Terms of the agreement were not disclosed.

8 Jul 2010

Dragon Pharma announces sufficient votes based on receipt of preliminary proxies to approve Merger

Dragon Pharmaceutical Inc. announced that based on the receipt of preliminary proxies, the Company believes that it has sufficient votes to approve the Agreement and Plan of Merger by and among Dragon, Chief Respect Limited, Datong Investment Inc., a subsidiary of Chief Respect Limited, and Mr. Yanlin Han.

8 Jul 2010

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.

8 Jul 2010

Oramed Pharmaceuticals signs MSA with sanofi-aventis

Oramed Pharmaceuticals Inc., a developer of oral delivery systems, today announced that Oramed entered into a Manufacturing Supply Agreement with sanofi-aventis. According to the MSA, sanofi-aventis will supply Oramed with specified quantities of recombinant human insulin to be used by Oramed for its clinical trials in the USA.

8 Jul 2010

MonoSol partner Strativa receives FDA approval for Zuplenz OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a. of Switzerland and Labtec GmbH of Germany, today announced that its partner, Strativa Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for Zuplenz® oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

8 Jul 2010

Crooks defraud health care system with fake insurance plans and phony Medicare, Medicaid claims

"Massive unemployment and a changing health care system is creating a breeding ground for con artists." Fake health insurance is one of the "fastest growing scams." Advertisements for such products are "stapled to neighborhood telephone polls, flyers left on your car or maybe you'll get a phone call from someone who's selling health insurance at extremely low rates, as low as $29.99 a month in some cases, says Jim Quiggle of the Coalition Against Insurance Fraud. The sad truth is that often these bogus policies pay little or nothing on claims, leaving consumers with exorbitant medical bills" (Haley, 7/6).

8 Jul 2010

Winston submits NDA for CIVANEX to U.S. FDA

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its civamide (zucapsaicin) 0.075% cream, CIVANEX®, for the treatment of signs and symptoms of osteoarthritis of the knee.

7 Jul 2010

Pharmaceuticals News and Research

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Alimera Sciences submits MAA for Iluvien to MHRA

Shire files patent infringement lawsuit against Zydus

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Jubilant Organosys Board approves amalgamation of SML & PMSL and demerger of APP business

Biopharmaceutical Nanotechnology Scientific Forum to take place in Philadelphia between August 16-18

Article related to MN-166 mechanism of action included in PNAS USA

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

UTHealth Biotechnology Commercialization Center leases over three-quarters of available space

Optics Express publishes special focus issue on lung cancer imaging research

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

New York Times examines India's growing influence on global drug industry

SurModics licenses biodegradable polymer implant technology to Clinuvel

Dragon Pharma announces sufficient votes based on receipt of preliminary proxies to approve Merger

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Oramed Pharmaceuticals signs MSA with sanofi-aventis

MonoSol partner Strativa receives FDA approval for Zuplenz OSF

Crooks defraud health care system with fake insurance plans and phony Medicare, Medicaid claims

Winston submits NDA for CIVANEX to U.S. FDA

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence